SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 26, 2003; DOI 10.1182/blood-2003-03-0665. This Article Full Text (PDF) All Versions of this Article: 2003-03-0665v1 102/8/3043    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gorin, N. C Articles by Frassoni, F. Search for Related Content PubMed PubMed Citation Articles by Gorin, N. C Articles by Frassoni, F. Social Bookmarking                   What's this? Submitted March 5, 2003 Accepted May 14, 2003 Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of the dose and the source of stem cells; better outcome with rich marrow Norbert C Gorin*, Myriam Labopin, Vanderson Rocha, William Arcese, Meral Beksac, Eliane Gluckman, Olle Ringden, Tapani Ruutu, Josy Reiffers, Giuseppe Bandini, M Falda, P Zikos, R Willemze, and Francesco Frassoni Department of Hematology, Hopital Saint-Antoine, Paris, France Department of Hematology, Hopital Saint Louis, Paris, France Department of Hematology, Universita La Sapienza, Rome, Italy Department of Hematology, Ibni Sina Hospital, Ankara, Turkey Department of Hematology, University Hospital, Huddinge, Sweden Department of Hematology, University Central Hospital, Helsinki, Finland Department of Hematology, Hopital Haut-Leveque, Pessac, France Department of Hematology, Hospital San Orsola, Bologna, Italy Department of Hematology, Azienda Ospedaliera S Giovanni, Turin, Italy Department of Hematology, University Medical School, Patras, Greece Department of Hematology, University Hospital, Leiden, The Netherlands Department of Hematology, Ospedale San Martino, Genoa, Italy * Corresponding author; email: norbert-claude.gorin{at}sat.ap-hop-paris.fr. Background: Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in allografted patients, but the cell doses infused have not been considered especially for marrow. Material and methods: We studied retrospectively on the ALWP/EBMT registry 881 adult patients with Acute Myelocytic Leukaemia (AML), who received a non T depleted allogeneic BM (n=515) or mobilised PB (n=366) standard transplant, in CR1, from an HLA identical sibling, over a five year period from January 1994. Results: The BM cell dose ranged from 0.17 to 29x108/kg with a median of 2.7 x108/Kg. The PB cell dose ranged from 0.02 to 77x108/kg with a median of 9.3 x 108/kg. The median dose for patients receiving BM (2.7 x108/Kg) gave the greatest discrimination. In multivariate analyses, high dose BM compared to PB, was associated with lower TRM (RR = 0.61; 95% CI 0.39-0.98; p=0.04), better Leukemia Free Survival (RR =0.65; 95% CI 0.46-0.91; p= 0.013), and better Overall Survival (RR = 0.64 ; 95% CI 0.44-0.92; p=0.016). Conclusion: The present study in patients with AML allografted in first remission, indicates a better outcome with marrow as compared to PB, when the dose of marrow infused is rich. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. A. Pulsipher, P. Chitphakdithai, B. R. Logan, S. F. Leitman, P. Anderlini, J. P. Klein, M. M. Horowitz, J. P. Miller, R. J. King, and D. L. Confer Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose Blood, September 24, 2009; 114(13): 2606 - 2616. [Abstract] [Full Text] [PDF] E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, January 1, 2009; 94(1): 102 - 112. [Abstract] [Full Text] [PDF] F. Ciceri, M. Labopin, F. Aversa, J. M. Rowe, D. Bunjes, P. Lewalle, A. Nagler, P. Di Bartolomeo, J. F. Lacerda, M. T. Lupo Stanghellini, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation Blood, November 1, 2008; 112(9): 3574 - 3581. [Abstract] [Full Text] [PDF] N.-C. Gorin, M. Labopin, J.-M. Boiron, N. Theorin, T. Littlewood, S. Slavin, H. Greinix, J. Y. Cahn, E. P. Alessandrino, A. Rambaldi, et al. Results of Genoidentical Hemopoietic Stem Cell Transplantation With Reduced Intensity Conditioning for Acute Myelocytic Leukemia: Higher Doses of Stem Cells Infused Benefit Patients Receiving Transplants in Second Remission or Beyond--The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation J. Clin. Oncol., August 20, 2006; 24(24): 3959 - 3966. [Abstract] [Full Text] [PDF] D.-P. Lu, L. Dong, T. Wu, X.-J. Huang, M.-J. Zhang, W. Han, H. Chen, D.-H. Liu, Z.-Y. Gao, Y.-H. Chen, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation Blood, April 15, 2006; 107(8): 3065 - 3073. [Abstract] [Full Text] [PDF] D. A. Wall Allogeneic Peripheral Blood Versus Bone Marrow Transplantation: Children Are Small Adults and More J. Clin. Oncol., December 15, 2004; 22(24): 4865 - 4866. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020